The three Aspen Pharmacare cancer medicines being probed by the Competition Commission have a collective annual turnover of just R3m, and have never seen price increases outside the regulatory framework overseen by the health department, the company said on Wednesday. The commission announced on Tuesday that it was investigating the price of cancer drugs made by Aspen Pharmacare, Roche Holdings, and Pfizer. The commission said it was investigating Aspen for suspected abuse of market dominance, as there were no rival products for its cancer drugs Leukeran, Alkeran and Myleran. JSE-listed generic drugmaker Aspen Pharmacare said earlier on Wednesday that the drugs were all off-patent, and had been for some time.

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as articles from our international business news partners; ProfileData financial data; and digital access to the Sunday Times and Sunday Times Daily.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00. Got a subscription voucher? Redeem it now